Speaking publicly for the first time about the USAID freeze, WHO director-general Dr Tedros has asked the US to reconsider ...

Royalty Pharma has signed a deal to pay Biogen $250m to support the development of its late-stage experimental lupus ...

TriNetX has collaborated with Fujitsu to establish TriNetX Japan KK, a JV aimed at accelerating healthcare research and ...

AbbVie has entered a partnership and option-to-license agreement with Xilio for tumour-activated, antibody-based ...

Catalent, a global contract development and manufacturing organization (CDMO), has been recognized with two awards in the 2024 Pharmaceutical Technology Excellence Awards in the Innovation and Social ...

Trump's tariffs will not only impact sponsors, but higher costs will ripple down the clinical trial supply chain in the US.

The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.

GlobalData’s Revati Tatake discussed key trends in biopharma which are set to have an impact in 2025 and beyond.

Lundbeck has received the US FDA fast track designation for amlenetug, a potential treatment for multiple system atrophy (MSA ...